nach oben

Wiener klinische Wochenschrift

Erschienen in:

01.06.2014 | case report

Liver hepatotoxicity associated with pantoprazole: a rare case report

verfasst von: Dr. Mehmet Aslan, Yilmaz Celik, Sevdegul Karadas, Sehmus Olmez, Adem Cifci

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 11-12/2014

Einloggen, um Zugang zu erhalten

Summary

Hepatotoxicity may occasionally develop over the course of treatment with proton pump inhibitors (PPIs). Although skin reactions, interstitial nephritis, pancytopenia, anaphylaxis, and generalized edema have been reported to be associated with PPIs, hepatotoxicity associated with oral pantoprazole is very rare. In this report, we present a case of hepatotoxicity in a 35-year-old man who received pantoprazole (40 mg/day) for acute gastritis. One week after discontinuation of pantoprazole, his liver function began to improve, and the patient gradually fully recovered. Although this toxicity occurs only infrequently, pantoprazole should be considered as a rare hepatotoxic agent in the literature.

Vorheriger Artikel Evaluation of 6- and 12-month supervised exercise training on strength and endurance parameters in patients with peripheral arterial disease

Nächster Artikel MedUni Wien Researcher of the Month, Juni 2014

Bjornsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010;32:3–13.PubMed

Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Proton pump inhibitors versus H2-antagonists: a metaanalysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther. 2001;15:917–26.PubMedCrossRef

Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM. Meta-analysis: proton pump inhibitors vs. H₂-receptor antagonists-their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;18:757–66.PubMedCrossRef

Hoogerwerf WA, Pasricha PJ. Agents used for control of gastric acidity and treatment of peptic ulcers and gastroesophageal reflux disease. In: Brunton L, Lazo J, Parker K, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001. pp. 1007–9.

Corleto VD, Festa S, Di Giulio E, Annibale B. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes. 2013 Dec 4; 21(1):3–8.

Tanaka M, Yamazaki H, Ryokawa Y, Hakusui H, Nakamichi N, Sekino H. Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor, after single and multiple oral doses in healthy Japanese volunteers. Int J Clin Pharmacol Ther. 1996;34:415–9.PubMed

Meyer UA. Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996;69:203–9.PubMedCentralPubMed

Jose J, Saravu K, Khera K, Jimmy B, Shastry BA. Acute interstitial nephritis related to lansoprazole administration. J Pak Med Assoc. 2008;58(4):206–7.PubMed

Lai HC, Hsu SW, Lu CH, Ma HI, Cherng CH, Hung NK, Wu CT. Anaphylaxis to pantoprazole during general anesthesia. J Anesth. 2011;25(4):606–8.PubMedCrossRef

10.

Gouraud A, Vochelle V, Descotes J, Vial T. Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole. Clin Drug Investig. 2010;30(8):559–63.PubMedCrossRef

11.

Brunner G, Athmann C, Boldt JH. Reversible peripheral edema in female patients taking proton pump inhibitors for peptic acid diseases. Dig Dis Sci. 2001;46:993–6.PubMedCrossRef

12.

Manthappa M, Raviraja V, Nishant N, Lorraine D. Pantoprazole induced generalized edema. Calicut Med J. 2009;7(4):e4.

13.

Sennaroglu E, Karakan S, Kayatas M, Akdur S, Genc H, Karakan T, Ucler R, Ozisler C, Urun Y. Reversible edema in a male patient taking parenteral pantoprazole infusion for pyloric stenosis. Dig Dis Sci. 2006;51:121–2.PubMedCrossRef

14.

Johnstone D, Berger C, Fleckman P. Acute fulminant hepatitis after treatment with rabeprazole and terbinafine. Arch Intern Med. 2001;161(13):1677–8.PubMedCrossRef

15.

Sandig C, Flechtenmacher C, Stremmel W, Eisenbach C. Pantoprazole induces severe acute hepatitis. Z Gastroenterol. 2011;49(2):207–10.PubMedCrossRef

16.

Wellhöfer B. Pantoprazole-induced hepatitis. Dtsch Med Wochenschr. 2003;128(27):1502.PubMed

17.

Cordes A, Vogt W, Maier KP. Pantoprazole-induced hepatitis. Dtsch Med Wochenschr. 2003;128(12):611–4.PubMedCrossRef

18.

Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22:145–55.PubMedCrossRef

19.

Ferron GM, Preston RA, Noveck RJ, Pockros P, Mayer P, Getsy J, Turner M, Abell M, Paul J. Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Clin Ther. 2001;23(8):1180–92.PubMedCrossRef

20.

Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25–35.PubMedCentralPubMedCrossRef

21.

Darabi K. Proton-pump-inhibitor-induced hepatitis. South Med J. 2005;98(8):844–5.PubMedCrossRef

22.

Yusoff IF, Nairn P, Morgan CA. Multiple organ failure related to pantoprazole. Aust N Z J Med. 1999;29(6):833–4.PubMedCrossRef

Titel: Liver hepatotoxicity associated with pantoprazole: a rare case report
verfasst von: Dr. Mehmet Aslan
Yilmaz Celik
Sevdegul Karadas
Sehmus Olmez
Adem Cifci
Publikationsdatum: 01.06.2014
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 11-12/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-014-0535-3

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11-12/2014

Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD

Unilateral olfactory bulb volume loss due to arteriovenous malformation

Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings

ÖGIM Fortbildungsveranstaltungen 2014

Evaluation of 6- and 12-month supervised exercise training on strength and endurance parameters in patients with peripheral arterial disease

Is a complete blood cell count useful in determining the prognosis of pulmonary embolism?